Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00940004 | Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01530698 | Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients | completed | Phase 1 / Phase 2 | 28 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00976573 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 149 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00060333 | Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma | completed | Phase 2 | 20 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 17, 2017 | clinicaltrials |
| NCT01781026 | Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | completed | Phase 2 | 2 | Yale UniversityOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00003895 | Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00553306 | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00450372 | Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 38 | University of MiamiOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00109005 | Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT01189383 | IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 20 | Baylor Research InstituteOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01619774 | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2016 | clinicaltrials |
| NCT00256230 | Disulfiram in Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 7 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00424515 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma(BUS255) | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00577382 | SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | completed | Phase 2 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01251978 | Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) | completed | Phase 2 | 10 | New England Retina AssociatesOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT01133977 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 97 | Eisai Inc.INDUSTRY | 5 | Oct 10, 2016 | clinicaltrials |
| NCT00135408 | A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide | completed | Phase 2 | 115 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 28, 2016 | clinicaltrials |
| NCT00289627 | A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 155 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2016 | clinicaltrials |
| NCT01278940 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 31 | Oslo University HospitalOTHER | 0 | Aug 15, 2016 | clinicaltrials |
| NCT01216696 | Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1(CTLA4 NY-ESO-1) | completed | Phase 2 | 25 | National Center for Tumor Diseases, HeidelbergOTHER | 1 | Aug 12, 2016 | clinicaltrials |
| NCT01248936 | A Study of RO5185426 in Patients With Metastatic Melanoma | completed | Phase 2 | 374 | Hoffmann-La RocheINDUSTRY | 1 | Aug 12, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00948480 | Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells(DCVaccineMel) | completed | Phase 2 | 56 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jul 15, 2016 | clinicaltrials |
| NCT00005610 | Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung | completed | Phase 2 | 28 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00098553 | Everolimus in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 53 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02285413 | Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients | completed | Phase 2 | 54 | Radboud University Medical CenterOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00004104 | Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01990859 | Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients | completed | Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01455259 | Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Uppsala UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00738361 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | completed | Phase 2 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00588341 | Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT02662725 | Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases(IPI+RTS) | completed | Phase 2 | 73 | University Hospital, LilleOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01435369 | Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma | completed | Phase 2 | 103 | Medivation, Inc.INDUSTRY | 2 | Jan 21, 2016 | clinicaltrials |
| NCT01983124 | Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib(BeyPro1) | completed | Phase 2 | 31 | Paola QueiroloOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00462982 | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT00289016 | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | completed | Phase 2 | 50 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT02574260 | An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) | completed | Phase 2 | 3 | BioVex LimitedINDUSTRY | 0 | Dec 17, 2015 | clinicaltrials |
| NCT00185302 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma | completed | Phase 2 | 28 | BayerINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT00257465 | Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma | completed | Phase 1 / Phase 2 | 82 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00096382 | Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00923195 | Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00665470 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | completed | Phase 2 | 158 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 12, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2017source: clinicaltrials